Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-08-28
2007-08-28
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C424S278100
Reexamination Certificate
active
10938695
ABSTRACT:
This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.
REFERENCES:
patent: 4716038 (1987-12-01), Stanford et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5578300 (1996-11-01), Schmidt et al.
patent: 5580563 (1996-12-01), Tam
patent: 5599545 (1997-02-01), Stanford et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5858368 (1999-01-01), Smith et al.
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6007806 (1999-12-01), Lathe et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6143299 (2000-11-01), Srivastava
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6322790 (2001-11-01), Srivastava
patent: 6335183 (2002-01-01), Young et al.
patent: 6338952 (2002-01-01), Young et al.
patent: 0 262 710 (1988-04-01), None
patent: 0 322 990 (1989-07-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO85/05034 (1985-11-01), None
patent: WO88/00974 (1988-02-01), None
patent: WO88/05823 (1988-08-01), None
patent: WO88/06591 (1988-09-01), None
patent: WO89/12455 (1989-12-01), None
patent: WO90/15873 (1990-12-01), None
patent: WO91/02542 (1991-03-01), None
patent: WO91/15572 (1991-10-01), None
patent: WO92/08484 (1992-05-01), None
patent: WO92/08488 (1992-05-01), None
patent: WO93/17712 (1993-09-01), None
patent: WO94/03208 (1994-02-01), None
patent: WO94/29459 (1994-12-01), None
patent: WO95/24923 (1995-09-01), None
patent: WO95 31994 (1995-11-01), None
patent: WO96/10421 (1996-04-01), None
patent: WO96 19496 (1996-06-01), None
patent: WO96 26277 (1996-08-01), None
patent: WO97 06821 (1997-02-01), None
patent: WO9710000 (1997-03-01), None
patent: WO97/26910 (1997-07-01), None
patent: WO98/23735 (1998-06-01), None
patent: WO98/35705 (1998-08-01), None
K. Suzue et al., “Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p. 24”,J. of Immunology, 156:873-879 (1996).
T. De Gruijl et al., “T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection”,J. of General Virology, 77:2183-2191 (1996).
Hungarian Patent Office Novelty Search Report dated Sep. 12, 2002.
International Search Report (Application No. PCT/CA 98/00246) dated Sep. 30, 1998.
Berkner, “Development of Adenovirus Vectors for the Expression of Heterologous Genes,”BioTechniques 6:616-629 (1988).
Cason et al., “Towards Vaccines Against Human Papillomavirus Type-16 Genital Infections,”Vaccine 11:603-611 (1993).
Gupta et al., “Adjuvants for Human Vaccines—Current Status, Problems and Future Prospects,”Vaccine 13:1263-1276 (1995).
Jenkins et al., “An Antigen Chimera of Poliovirus Induces Antibodies Against Human Papillomavirus Type 16,”J. Virol. 64:1201-1206 (1990).
Miller et al., “Improved Retroviral Vectors for Gene Transfer and Expression,”BioTechniques 7:980-990 (1989).
Nieland et al., “Isolation of an Immunodominant Viral Peptide that is Endogenously Bound to the Stress Protein GP96/GRP94,”Proc. Natl. Acad. Sci. USA 93:6135-6139 (1996).
Power et al., “Induction of Protective Immunity in Rodents by Vaccination with a Prokaryotically Expressed Recombinant Fusion Protein Containing a Respiratory Syncytial Virus G Protein Fragment,”Virology 230:155-166 (1997).
Schiller et al., “Papillomavirus Vaccines: Current Status and Future Prospects,”Adv. Dermatol. 11:355-380 (1996).
Srivastava et al., “Heat Shock Proteins Transfer Peptides During Antigen Processing and CTL Priming,”Immunogenetics 39:93-98 (1994).
Steller et al., “Human Papillomavirus Immunology and Vaccine Prospects,”Monog. Natl. Cancer Inst. 21:145-148 (1996).
Sun et al., “An Antigenic Recombinant Fusion Protein fromTrichinella spiralisInduces a Protective Response in BALB/c Mice,”J. Helmint. 68:89-91 (1994).
Tindle et al., “Chimeric Hepatitis B Core Antigen Particles Containing B- and Th-Epitopes of Human Papillomavirus Type 16 E7 Protein Induce Specific Antibody and T-Helper Responses in Immunised Mice,”Virology 200:547-557 (1994).
Tindle et al., “A Vaccine Conjugate of ‘ISCAR’ Immunocarrier and Peptide Epitopes of the E7 Cervical Cancer-Associated Protein of Human Papillomavirus Type 16 Elicits Specific Th1- and Th2-Type Responses in Immunized Mice in the Absence of Oil-Based Adjuvants,”Clin. Exp. Immunol. 101:265-271 (1995).
Tindle et al., “Human Papillomavirus Vaccines for Cervical Cancer,”Curr. Opin. Immunol. 8:643-650 (1996).
Wang et al., “Second-Generation Adenovirus Vectors,”Nature Medicine 2:714-716 (1996).
Wu et al., “Engineering an Intracellular Pathway for Major Histocompatibility Complex Class II Presentation of Antigens,”Proc. Natl. Acad. Sci. USA 92:11671-11675 (1995).
Agranovsky et al., “Putative 65 kDa Protein of Beet Yellows Closterovirus Is a Homologue of HSP70 Heat Shock Proteins,” J. Mol. Biol., 217:603-610 (1991).
Ardeshir et al., “A 75 Kd Merozoite Surface Protein of Plasmodium Falciparum which is Related to the 70 kd Heat-Shock Proteins,” EMBO J., 6(2):493-499 (1987).
Arnosti et al., “Characterization of heat shock inBacillus subtilis,” J. Bact., 168(3):1243-1249 (Dec. 1986).
Arrigo and Welch, “Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein”, J. Biol. Chem., 262(32):15359-15369 (1987).
Barrios et al., “Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and DnaK proteins requires cross-linking with antigen,” Clin. Exp. Immunol., 98:229-233 (1994).
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol., 22:1365-1372 (1992).
Beech et al., “CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis,” J. Immunol. 159:3692-3697 (1997).
Bertelli et al., “BCG-In
Chu N. Randall
Mizzen Lee A.
Wu Huacheng Bill
Crews Lee
Fish & Richardson P.C.
Salimi Ali R.
Stressgen Biotechnologies Corporation
LandOfFree
Immune responses against HPV antigens elicited by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune responses against HPV antigens elicited by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune responses against HPV antigens elicited by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3849235